Technical Analysis for EXEL - Exelixis, Inc.

Grade Last Price % Change Price Change
D 22.3 2.95% 0.64
EXEL closed up 2.95 percent on Monday, March 1, 2021, on 60 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Flat
Historical EXEL trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
50 DMA Resistance Bearish 2.95%
MACD Bearish Centerline Cross Bearish 2.95%
Bollinger Band Squeeze Range Contraction 2.95%
Bearish Engulfing Bearish 1.55%
Fell Below 200 DMA Bearish 1.55%
Fell Below 20 DMA Bearish 1.55%
Fell Below 50 DMA Bearish 1.55%
Bollinger Band Squeeze Range Contraction 1.55%
Older End-of-Day Signals for EXEL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 5 hours ago
Up 3% about 5 hours ago
Rose Above 10 DMA about 5 hours ago
Up 2% about 9 hours ago
Rose Above 50 DMA about 9 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Exelixis, Inc. Description

Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Treatment Of Cancer Prostate Cancer Thyroid Tyrosine Kinase Glaxosmithkline Progressive Pivotal Protein Kinase Inhibitor Resistant Prostate Cancer Small Molecule Therapies Tyrosine Kinase Inhibitors Cyclopropanes Thyroid Cancer Metastatic Castration Resistant Prostate Cancer Receptor Tyrosine Kinase Daiichi Sankyo Tyrosine Kinases

Is EXEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.8
52 Week Low 13.67
Average Volume 2,415,330
200-Day Moving Average 22.49
50-Day Moving Average 22.08
20-Day Moving Average 22.48
10-Day Moving Average 22.21
Average True Range 0.89
ADX 10.94
+DI 18.86
-DI 23.38
Chandelier Exit (Long, 3 ATRs ) 21.32
Chandelier Exit (Short, 3 ATRs ) 23.93
Upper Bollinger Band 23.53
Lower Bollinger Band 21.43
Percent B (%b) 0.41
BandWidth 9.36
MACD Line -0.04
MACD Signal Line 0.05
MACD Histogram -0.0917
Fundamentals Value
Market Cap 6.92 Billion
Num Shares 310 Million
EPS 0.48
Price-to-Earnings (P/E) Ratio 46.56
Price-to-Sales 6.23
Price-to-Book 3.16
PEG Ratio 0.54
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.53
Resistance 3 (R3) 23.45 22.95 23.33
Resistance 2 (R2) 22.95 22.64 23.00 23.26
Resistance 1 (R1) 22.63 22.45 22.79 22.71 23.19
Pivot Point 22.13 22.13 22.22 22.18 22.13
Support 1 (S1) 21.81 21.82 21.97 21.89 21.41
Support 2 (S2) 21.31 21.63 21.36 21.34
Support 3 (S3) 20.99 21.31 21.28
Support 4 (S4) 21.07